Luca Visani
@LucaVisani2
Followers
188
Following
127
Media
26
Statuses
120
Clinical Oncologist - Clinical Trials Coordinator Breast Unit AOU Careggi
Firenze, Toscana
Joined January 2021
RT @Icro_Meattini: Welcome back @myESMO #ESTRO25 .Stronger, together 💪. 👉 Chairing with @curijoey ESMO President Elect - the ESTRO-ESMO Sym….
0
13
0
Esclusive RT vs ET for older women >70y with pT1N0 luminal A tumors. Less impact on HRQoL with RT at the first interim analysis. Wonderful presentation by @Icro_Meattini, very well done! Proud to be part of this project. See the concomitant publication on Lancet Oncology! #SABCS
0
3
9
RT @Icro_Meattini: Association between risk reducing surgeries and survival in young BRCA carriers with #BreastCancer . Accumulating crucia….
0
17
0
EMBER-3: imlunestrant alone or imlunestrant plus abemaciclib vs fulvestrant in patients previously treated with ET (prior CDK4/6i in 60% of patients). Imlunestrant effective as monotherapy in ESR1m patients, in combination with abema benefit showed for all patients #SABCS24
0
0
1
RT @EORTC_BCG: Great @EORTC_BCG Autumn Meeting in Paris @institut_curie ! 2 days of insightful presentations and productive discussions on….
0
5
0
RT @GiulioFrancoli1: Very Happy to present early results from STARR trial (NCT05455736) at ASTRO! #ASTRO24 ,@dicataldovanes1 ,@PietroGarlat….
0
11
0
Multicentre retrospective study comparing safety outcomes of BC patients treated with T-DXd with or without concomitant RT (379P). No impact on acute toxicity development and T-DXd discontinuation ‼️@Icro_Meattini @i_ratosa @CarlottaB @VSalvestrini @andMORand #ESMO2024 #ESMO24
0
2
11
RT @Icro_Meattini: Neoadjuvant pembrolizumab or placebo plus chemotherapy for triple negative #breastcancer - Overall Survival results from….
0
11
0
Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer
0
0
1
RT @stolaney1: Registry of stage 1 TNBC (>1100 pts).pCR: 57.3%.pCR associated w/ better OS (HR 0.29). @OncoAlert #bcsm #ESMO24
https://t.co….
0
7
0
Magnitude of benefit in iDFS with adjuvant ribociclib plus NSAI seems to be higher for younger patients. #ESMO2024 #ESMO24 #breastcancer
0
0
1
Confirmed importance of ovarian suppression (especially plus AI) for premenopausal HR+/HER2+ patients, irrespectively of adjuvant trastuzumab administration in the HERA trial #ESMO2024 #ESMO24 #breastcancer
0
0
1
RT @GiulioFrancoli1: PERSIAN trial will offer the unique opportunity to evaluate SBRT in a selected cohort of oligometastatic metachronous….
acrobat.adobe.com
Click or tap to view this file.
0
6
0
RT @matteolambe: Presented today at #SABCS23 and published in @JAMA_current results of our study showing the feasibility and safety of #pre….
0
70
0
RT @Oncoinfo_it: #SABCS23 | @matteolambe: supporting data for TD-Xd intracranial activity in both stable and active brain metastasis and in….
0
10
0
RT @Oncoinfo_it: #SABCS23 | @Icro_Meattini: good news from San Antonio about the integration of #radiationtherapy with TD-Xd in #breastcanc….
0
5
0
First preliminary encouraging data from our institution on the combination of intracranial and extracranial RT ☢️ with T-DXd‼️No significant association with G3 or higher acute toxicity. Room for future evaluation in larger cohorts. #SABCS23 #BreastCancer @Oncoinfo_it @OncoAlert
1
0
8
RT @ErikaHamilton9: #DEBBRAH cohort 5 of TDXd tx for pts with leptomeningeal disease. 7 pts: 4 HER-2 low, 3 HER-2 +.OS = 13.3 months.mPFS =….
0
23
0